Clinical Daily Summary: What Happened on November 8, 2026

Semaglutide reduced heart-filling pressures in obesity-related HFpEF

Researchers randomly assigned 81 participants to weekly semaglutide or placebo in a double-blind trial lasting 52 weeks.1 During exercise, pulmonary artery wedge pressure, a measure of pressure inside the heart, fell by 9.8 mmHg with semaglutide and rose by 0.9 mmHg with placebo.1 The estimated difference between groups was −10.6 mmHg.1

At rest, the estimated reduction with semaglutide was 7.1 mmHg greater than with placebo.1 Hemodynamic remission, defined by specified pressure thresholds, occurred in 53.7% of the semaglutide group and 7.4% of the placebo group.1 Novo Nordisk supplied the semaglutide and matching placebo.1

Imaging substudy connects heart-function changes with pressure reductions

In a prespecified magnetic resonance substudy, 49 participants had scans at the start of the trial and after 52 weeks.2 Compared with placebo, semaglutide improved left atrial reservoir strain by 5.7% and the indexed early filling rate of the left ventricle by 0.64 s−1.2 Both measures were associated with lower exercise pulmonary artery wedge pressure.2

The substudy also found lower left ventricular mass, more physiologic ventricular geometry, and improved right ventricular function and mechanics in both ventricles.2 The authors said these changes may help explain semaglutide’s hemodynamic effects in people with obesity-related HFpEF.2

Also published

• When genetic medicine enters the inner ear European Biotechnology
• STAT+: Why the latest heart drug failures should make us all more skeptical of AI hype STAT Biotech